Natera, Inc. $NTRA Shares Purchased by Corient Private Wealth LP

Key Points

• Corient Private Wealth LP increased its Natera stake by 39.2% in the second quarter, owning 17,722 shares valued at approximately $4.8 million. Institutional investors and hedge funds collectively own 99.9% of Natera’s stock.
• Analyst sentiment remains positive, with Natera receiving a consensus “Moderate Buy” rating and an average price target of $330.83; Citigroup recently raised its target to $365, while RBC upgraded the stock to “Buy.”
• Natera shares opened at $369.39, near their 12-month high, after the company reported 37.7% year-over-year revenue growth and quarterly revenue of $752.75 million, exceeding analyst expectations.

Corient Private Wealth LP boosted its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 39.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 17,722 shares of the medical research company's stock after buying an additional 4,993 shares during the period. Corient Private Wealth LP's holdings in Natera were worth $4,811,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NTRA. Amundi lifted its stake in shares of Natera by 3.0% during the second quarter. Amundi now owns 315,654 shares of the medical research company's stock worth $85,684,000 after purchasing an additional 9,338 shares in the last quarter. HighTower Advisors LLC lifted its position in Natera by 29.8% during the 2nd quarter. HighTower Advisors LLC now owns 140,931 shares of the medical research company's stock worth $38,256,000 after acquiring an additional 32,395 shares in the last quarter. Wedmont Private Capital lifted its position in Natera by 11.1% during the 2nd quarter. Wedmont Private Capital now owns 1,768 shares of the medical research company's stock worth $477,000 after acquiring an additional 177 shares in the last quarter. HB Wealth Management LLC boosted its holdings in Natera by 29.6% in the 2nd quarter. HB Wealth Management LLC now owns 3,987 shares of the medical research company's stock worth $1,082,000 after acquiring an additional 911 shares during the period. Finally, Saudi Central Bank boosted its holdings in Natera by 94.3% in the 2nd quarter. Saudi Central Bank now owns 9,425 shares of the medical research company's stock worth $2,558,000 after acquiring an additional 4,575 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on NTRA shares. Royal Bank Of Canada upgraded shares of Natera from an "outperform" rating to a "buy" rating in a research note on Tuesday, September 8th. Wolfe Research assumed coverage on shares of Natera in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $260.00 target price for the company. The Goldman Sachs Group started coverage on shares of Natera in a report on Friday, June 5th. They set a "neutral" rating and a $245.00 price target for the company. Morgan Stanley reaffirmed an "overweight" rating and set a $355.00 price target on shares of Natera in a research note on Monday, August 10th. Finally, Citigroup upped their price objective on shares of Natera from $315.00 to $365.00 and gave the company a "buy" rating in a research report on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $330.83.

Natera Trading Up 0.8%

Shares of NASDAQ:NTRA opened at $369.39 on Friday. The firm has a market cap of $53.24 billion, a PE ratio of -271.61 and a beta of 1.54. The company has a fifty day simple moving average of $305.45 and a 200 day simple moving average of $246.69. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $369.69.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm's revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period last year, the business earned ($0.74) EPS. As a group, equities research analysts forecast that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Insider Activity at Natera

In related news, insider John Fesko sold 6,517 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the completion of the sale, the insider owned 197,257 shares of the company's stock, valued at $63,424,043.21. This represents a 3.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 15,160 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the sale, the insider owned 110,859 shares in the company, valued at approximately $36,238,698.51. This trade represents a 12.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 68,242 shares of company stock worth $19,301,534 over the last quarter. 5.05% of the stock is owned by corporate insiders.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services based on cell-free DNA and other genomic technologies. The company focuses on reproductive health, oncology and organ health, providing tests intended to support screening, diagnosis, treatment planning and disease monitoring.

Its reproductive health portfolio includes Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.